- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Samsung Bioepis Initiates Phase 3 Ustekinumab Trial
Samsung Bioepis launches a potential pivotal trial for its SB17 ustekinumab biosimilar candidate.
Just days after Bio-Thera announced initiation of a phase 3 study of patients receiving a candidate ustekinumab biosimilar, Samsung Bioepis said that it, too, has begun a phase 3 clinical trial for its own biosimilar version of this agent.
The reference ustekinumab product is Stelara, which commands a $5 billion market among patients with autoimmune diseases. Samsung’s trial will evaluate SB17 in patients with moderate-to-severe plaque psoriasis in a randomized, double-blind, multicenter analysis.
In the United States, Stelara is indicated for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderate-to-severe Crohn disease, and moderate-to-severe ulcerative colitis. The drug was first approved in 2009 and potentially could see the end of US patent protection in 2023.
If SB17 is approved for plaque psoriasis, physicians in the United States could extrapolate its use for other indications of the reference product.
Samsung Bioepis said it aims to enroll 464 patients in the phase 3 trial and randomize them 1:1 to either SB17 or the reference product via subcutaneous injection. At week 28, all patients on Stelara will be randomized to continue on Stelara or transition to SB17. A final assessment will be performed at week 52. The study’s estimated primary completion date is June 2022.
For more about Bio-Thera’s ustekinumab biosimilar development program, click here.
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: How Developers Can Expand Their Monoclonal Antibody Biosimilar Portfolio
March 24th 2025Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and technological feasibility, whereas other biologics encounter development challenges but may see increased adoption as regulatory frameworks advance.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
